AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15522126 — intervention group
Group type: COMPARATOR
Intervention: Water (0 g fat)
Number of subjects: 8
Study 11996260 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDCABG‐endo
Number of subjects: 190
Study 11996260 — intervention group
Group type: COMPARATOR
Intervention: MIDCABG‐conv
Number of subjects: 190
Study 11996260 — intervention group
Group type: COMPARATOR
Intervention: CABG‐conv
Number of subjects: 190
Study 9709846 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 644
Study 7913348 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 7913348 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine plus somatostatin
Number of subjects: 0
Study 2573768 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous catheter tunnelling (group B)
Number of subjects: 109
Study 2573768 — intervention group
Group type: COMPARATOR
Intervention: Traditional subclavian catheterisation (group A)
Number of subjects: 109
Study 2573768 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination of the catheter hub
Number of subjects: 109
Study 2573768 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin flora of nurses
Number of subjects: 109
Study 1102987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (50 mg twice daily) plus calcium carbonate (1 g four times daily)
Number of subjects: 26
Study 1102987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30
Study 31425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30
Study 31425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil with dexmedetomidine
Number of subjects: 30
Study 31425170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Remifentanil
Number of subjects: 30
Study 27632884 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-Hz vibration
Number of subjects: 10
Study 27632884 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-Hz vibration
Number of subjects: 10
Study 27632884 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control protocol)
Number of subjects: 10
Study 26251666 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (OO)
Number of subjects: 41
Study 26251666 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 41
Study 23758966 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported MVPA
Number of subjects: 257
Study 23758966 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectively measured MVPA
Number of subjects: 257
Study 21233779 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses (OR)
Number of subjects: 99
Study 21233779 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 99
Study 19713092 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil (SO), 10mL x 3 daily for 10 days
Number of subjects: 18
Study 19713092 — intervention group
Group type: EXPERIMENTAL
Intervention: Whale oil (WO), 10mL x 3 daily for 10 days
Number of subjects: 18
Study 19713092 — intervention group
Group type: COMPARATOR
Intervention: Soy oil (control)
Number of subjects: 18
Study 17597498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cignolini methodology (Qigong massage)
Number of subjects: 13
Study 15066805 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides biscuits
Number of subjects: 15
Study 15066805 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides biscuits
Number of subjects: 15
Study 11570684 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% polyacrylic acid (PAA) for 10 s, no rinsing
Number of subjects: 15
Study 11570684 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% PAA for 20 s, rinsed
Number of subjects: 15
Study 11570684 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% PAA for 25 s, rinsed
Number of subjects: 15
Study 11570684 — intervention group
Group type: EXPERIMENTAL
Intervention: 32% phosphoric acid for 15 s, rinsed
Number of subjects: 15
Study 11570684 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acid pretreatment)
Number of subjects: 15
Study 9768370 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone once daily for 12 weeks
Number of subjects: 30
Study 9768370 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo once daily for 12 weeks
Number of subjects: 30
Study 7849541 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake Group 1 (409 +/‐ 21 mg calcium/day)
Number of subjects: 55
Study 7849541 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake Group 2 (663 +/‐ 16 mg calcium/day)
Number of subjects: 55
Study 7849541 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake Group 3 (950 +/‐ 32 mg calcium/day)
Number of subjects: 55
Study 7849541 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake Group 4 (1437 +/‐ 124 mg calcium/day)
Number of subjects: 55
Study 2660862 — intervention group
Group type: EXPERIMENTAL
Intervention: Early consolidation with DATOP at lower dosage followed by maintenance chemotherapy
Number of subjects: 203
Study 2660862 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone
Number of subjects: 203
Study 1099598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 20
Study 1099598 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 20
Study 31759132 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine Explorer (automated segmentation and quantification program)
Number of subjects: 100
Study 31759132 — intervention group
Group type: COMPARATOR
Intervention: ImageJ (manual segmentation and quantification)
Number of subjects: 100
Study 31759132 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine Explorer (automated measurements)
Number of subjects: 100
Study 31021427 — intervention group
Group type: COMPARATOR
Intervention: 2008
Number of subjects: 24000
Study 31021427 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016
Number of subjects: 24000
Study 28521838 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Healthcare Choices (IHC) primary school resources (textbook and teachers' guide), nine lessons of 80 minutes each covering 12 key concepts.
Number of subjects: 120
Study 28521838 — intervention group
Group type: COMPARATOR
Intervention: Current primary school curriculum (control group).
Number of subjects: 120
Study 25853139 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strength training (SST)
Number of subjects: 41
Study 25853139 — intervention group
Group type: EXPERIMENTAL
Intervention: General fitness training (GFT)
Number of subjects: 41
Study 25853139 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information (REF)
Number of subjects: 41
Study 25853139 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CON)
Number of subjects: 41
Study 21884028 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin stimulating agents (ESA) - epoetin alfa
Number of subjects: 45
Study 21884028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21522071 — intervention group
Group type: EXPERIMENTAL
Intervention: Midthigh power clean
Number of subjects: 11
Study 21522071 — intervention group
Group type: EXPERIMENTAL
Intervention: Midthigh clean pull
Number of subjects: 11
Study 21522071 — intervention group
Group type: COMPARATOR
Intervention: Power clean
Number of subjects: 11
Study 21522071 — intervention group
Group type: COMPARATOR
Intervention: Hang-power clean
Number of subjects: 11
Study 18264870 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies for RCTs in drug and alcohol treatment
Number of subjects: 0
Study 18264870 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to patient participation
Number of subjects: 0
Study 17199193 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal eye spray (Tears Again)
Number of subjects: 74
Study 17199193 — intervention group
Group type: COMPARATOR
Intervention: Eye gel containing triglycerides (Liposic)
Number of subjects: 74
Study 15626589 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 50 mg daily for 5 consecutive days
Number of subjects: 10
Study 15626589 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for sex, age, and cardiovascular risk factors)
Number of subjects: 10
Study 15626589 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer patients (without aspirin)
Number of subjects: 10
Study 12663271 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-OB (80 mg weekly for 46 days)
Number of subjects: 22
Study 12663271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10052405 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 microg/kg daily IL-10
Number of subjects: 10
Study 10052405 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/kg 3 times per week IL-10
Number of subjects: 10
Study 10052405 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 treatment
Number of subjects: 10
Study 7552793 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative nutritional support for at least 10 days
Number of subjects: 0
Study 7552793 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 0
Study 2150187 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg etodolac twice a day
Number of subjects: 65
Study 2150187 — intervention group
Group type: COMPARATOR
Intervention: 20 mg piroxicam once a day
Number of subjects: 65
Study 7191309 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 60 mg acemetacin
Number of subjects: 20
Study 7191309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31665115 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG precipitation procedure
Number of subjects: 62
Study 31665115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobas® immunoassay
Number of subjects: 62
Study 31665115 — intervention group
Group type: EXPERIMENTAL
Intervention: Architect i2000® immunoassay
Number of subjects: 62
Study 31665115 — intervention group
Group type: EXPERIMENTAL
Intervention: Size‐exclusion chromatography (SEC)
Number of subjects: 62
Study 30593268 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-start GnRH antagonist protocol with estrogen priming followed by early follicular-phase GnRH antagonist treatment for 7 days before ovarian stimulation with gonadotropin
Number of subjects: 120
Study 30593268 — intervention group
Group type: COMPARATOR
Intervention: Standard GnRH antagonist protocol with estrogen priming
Number of subjects: 120
Study 26394294 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized education and mentored problem‐solving intervention via up to 10 telephone calls at 2‐week intervals.
Number of subjects: 153
Study 26394294 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 153
Study 25317794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic asthma patients (Group A and Group B)
Number of subjects: 42
Study 25317794 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 42
Study 22983600 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 218
Study 22983600 — intervention group
Group type: EXPERIMENTAL
Intervention: Present-centered therapy
Number of subjects: 218
Study 22983600 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who no longer met diagnostic criteria for PTSD
Number of subjects: 218
Study 20571434 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg over a 14-day period)
Number of subjects: 30
Study 20571434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18717374 — intervention group
Group type: EXPERIMENTAL
Intervention: All-ceramic restorations
Number of subjects: 30
Study 18717374 — intervention group
Group type: COMPARATOR
Intervention: Porcelain-fused-to-metal (PFM) restorations
Number of subjects: 30
Study 18717374 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of MT(Implant) and MT(Tooth) values
Number of subjects: 30
Study 16582545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-rich mineral water (281 mg/l)
Number of subjects: 22
Study 16582545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-rich mineral water (120 mg/l)
Number of subjects: 22
Study 16582545 — intervention group
Group type: COMPARATOR
Intervention: Low mineralized water (8 mg/l)
Number of subjects: 22
Study 16582545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg capsule (Magnesium‐Diasporal 150)
Number of subjects: 22
Study 15006256 — intervention group
Group type: EXPERIMENTAL
Intervention: RLX + low‐dose transdermal estrogen (RLX + E)
Number of subjects: 60
Study 15006256 — intervention group
Group type: COMPARATOR
Intervention: RLX + placebo
Number of subjects: 60
Study 15006256 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (combined)
Number of subjects: 60
Study 15006256 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II to Phase IV
Number of subjects: 60
Study 15006256 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II
Number of subjects: 60
Study 14674213 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine antigen assays (EIA) for symptomatic men
Number of subjects: 606
Study 14674213 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine antigen assays (EIA) for asymptomatic men
Number of subjects: 606
Study 8826517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sufentanil 1 microgram/kg given 5 min before induction of anaesthesia (group A)
Number of subjects: 39
Study 8826517 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil 1 microgram/kg given after ligation of the round ligaments of the uterus (group B)
Number of subjects: 39
Study 1421710 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high dose chemotherapy and autologous bone marrow transplantation (ABMT) rescue
Number of subjects: 28
Study 6607596 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preparation (24 hr of clear liquids plus two major laxatives plus tap-water enemas)
Number of subjects: 0
Study 6607596 — intervention group
Group type: COMPARATOR
Intervention: Colimmac lavage
Number of subjects: 0
Study 6607596 — intervention group
Group type: COMPARATOR
Intervention: Colimmac lavage plus one major laxative
Number of subjects: 0
Study 28862032 — intervention group
Group type: COMPARATOR
Intervention: No heparin pre-treatment (Control)
Number of subjects: 7144
Study 29573941 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib (oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily)
Number of subjects: 577
Study 29573941 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib (oral vemurafenib 960 mg twice daily)
Number of subjects: 577
Study 29573941 — intervention group
Group type: COMPARATOR
Intervention: Encorafenib (oral encorafenib 300 mg once daily)
Number of subjects: 577
Study 26701234 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg I/mL iodine concentration
Number of subjects: 50
Study 26701234 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg I/mL iodine concentration
Number of subjects: 50
Study 24586292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) administration
Number of subjects: 22
Study 24586292 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 24586292 — intervention group
Group type: COMPARATOR
Intervention: Children with CF (without LGG)
Number of subjects: 22
Study 23086791 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 158
Study 23086791 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 158
Study 21038410 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IFN‐α2a 180 μg subcutaneously weekly and weight‐based oral RBV 800 to 1,200 mg daily for 24 weeks
Number of subjects: 60
Study 21038410 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IFN‐α2a 180 μg subcutaneously weekly and weight‐based oral RBV 800 to 1,200 mg daily for 48 weeks
Number of subjects: 60
Study 18845650 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 units of oxytocin
Number of subjects: 80
Study 18845650 — intervention group
Group type: COMPARATOR
Intervention: 5 units of oxytocin
Number of subjects: 80
Study 15836749 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home educational intervention by peer health educators
Number of subjects: 150
Study 12581832 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole practice (practiced both parts of the 2:3 polyrhythm with pacing metronome tones)
Number of subjects: 36
Study 12581832 — intervention group
Group type: COMPARATOR
Intervention: Part practice (practiced each rhythm separately with corresponding pacing tone)
Number of subjects: 36
Study 12581832 — intervention group
Group type: EXPERIMENTAL
Intervention: Part/whole practice (practiced each rhythm separately with pacing tones for both rhythms)
Number of subjects: 36
Study 11563405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) at maximally tolerated doses administered orally prior to and continuing for 48 hours following surgery
Number of subjects: 75
Study 11563405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11563405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 75
Study 7862366 — intervention group
Group type: EXPERIMENTAL
Intervention: $5.00 gift certificate
Number of subjects: 205
Study 7862366 — intervention group
Group type: EXPERIMENTAL
Intervention: Gift certificate and a chance to win a $100 raffle
Number of subjects: 205
Study 7862366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentives)
Number of subjects: 205
Study 2036944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (45 min sessions on 9 days over 15 days)
Number of subjects: 14
Study 2036944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 14
Study 2036944 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific attention (control group)
Number of subjects: 14
Study 7076881 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support intervention and small group sessions
Number of subjects: 200
Study 7076881 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention groups
Number of subjects: 200
Study 31400513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention including behavior change goals, daily text messages with feedback, web-based weight gain graphs, health coaching, and a Facebook support group.
Number of subjects: 262
Study 31400513 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 262
Study 29160101 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (7.5 mg/mL ropivacaine)
Number of subjects: 57
Study 29160101 — intervention group
Group type: COMPARATOR
Intervention: Control group (spinal anesthesia only)
Number of subjects: 57
Study 27077987 — intervention group
Group type: EXPERIMENTAL
Intervention: IPASS intervention
Number of subjects: 185
Study 27077987 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 185
Study 24990880 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilizumab (humanized monoclonal antibody targeting M1 prime epitope)
Number of subjects: 0
Study 24990880 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilizumab
Number of subjects: 0
Study 24990880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22728756 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg once daily for those ≥13 years or weight‐based dosing for children 1‐12 years)
Number of subjects: 477
Study 22728756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 22728756 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 477
Study 19959338 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus mirtazapine 30 mg/day
Number of subjects: 40
Study 19959338 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 40
Study 18070637 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced injection (steroid, lidocaine, bupivacaine, and bicarbonate, neutral pH)
Number of subjects: 125
Study 18070637 — intervention group
Group type: COMPARATOR
Intervention: Standard injection (steroid, lidocaine, and bupivacaine alone, acidic pH)
Number of subjects: 125
Study 16140697 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including alcohol-based hand sanitizer and hand-hygiene education
Number of subjects: 292
Study 16140697 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only materials promoting good nutrition
Number of subjects: 292
Study 16140697 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sanitizer usage within intervention group
Number of subjects: 292
Study 12118873 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected typing pace
Number of subjects: 0
Study 12118873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast typing
Number of subjects: 0
Study 12118873 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative pace of typing
Number of subjects: 0
Study 10480502 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HbA1c results
Number of subjects: 1138
Study 10480502 — intervention group
Group type: COMPARATOR
Intervention: Conventional HbA1c results
Number of subjects: 1138
Study 10480502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1138
Study 8730527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary-fat screening instrument
Number of subjects: 0
Study 8730527 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Habits Questionnaire (FHQ)
Number of subjects: 0
Study 1908569 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcotrans Plus
Number of subjects: 96
Study 1908569 — intervention group
Group type: COMPARATOR
Intervention: Stryker‐CBC ConstaVAC
Number of subjects: 96
Study 1908569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 96
Study 6353278 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (intravenous, given for 2 days)
Number of subjects: 26
Study 6353278 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 26